Baidu
map

Nature:癌症药物“PD- 1 抑制剂”有可能促进肿瘤完全爆发

2017-04-02 佚名 来宝网

释放免疫系统的强大药物具有消灭晚期疾病患者一部分癌症的前景。但是最近的两项研究 1,2 表明,这些称为 PD- 1 抑制剂的疗法可能会在某些患者中发生反应,加速癌症的传播。现在科学家想要找出原因。最新的研究太小,无法证明医生是如何治疗患者的。但研究已经促使呼吁进行更大的临床试验,以探索旨在控制肿瘤的免疫治疗药物如何刺激他们。美国马里兰州贝塞斯达的美国国家癌症研究所癌症研究员 Elad Sharon

释放免疫系统的强大药物具有消灭晚期疾病患者一部分癌症的前景。但是最近的两项研究 1,2 表明,这些称为 PD- 1 抑制剂的疗法可能会在某些患者中发生反应,加速癌症的传播。现在科学家想要找出原因。

最新的研究太小,无法证明医生是如何治疗患者的。但研究已经促使呼吁进行更大的临床试验,以探索旨在控制肿瘤的免疫治疗药物如何刺激他们。

美国马里兰州贝塞斯达的美国国家癌症研究所癌症研究员 Elad Sharon 说:“需要的是更大的研究,使肿瘤图像可供外界科学家分析”。他还说:“我们应该做的事可能是更多地与其他分支机构交叉授粉,以观察免疫系统”。

Kurzrock 将笔记与同事进行了比较,发现他们每个患者的 PD- 1 抑制剂治疗期间肿瘤生长异常快。她的同事几天后回来,并指出患者共享同样罕见的遗传改变:癌症驱动基因 MDM2 或 MDM4 的额外拷贝。

警告标志

Kurzrock 开始询问,收集关于人类甚至实验室小鼠的轶事 - 其肿瘤在用免疫治疗后进展迅速。即使收集了几个来源的例子,她对发布结果感到很紧张。

同时,法国维勒瑞夫的古斯塔夫·鲁西研究所的研究人员也遇到了同样的问题。研究所肿瘤学家 CharlesFerté回忆说:“出席会议的有几位医生报告了 PD- 1 治疗的异常反应”。有些朋友和同事说:“我用这种药治疗了肺部病人,肿瘤在两周内完全爆发”。

Ferté及其同事决定对患者进行肿瘤生长的系统研究。去年 11 月,他们发表了他们的结果:131 人接受了抗 PD- 1 治疗,9%发展成为调查人员称之为“超前进”疾病,加速肿瘤生长。这种现象似乎在 65 岁以上的人中更常见。

3 月 28 日,Kurzrock 及其同事公布了 155 例接受 PD- 1 抑制剂和其他免疫疗法治疗的患者的资料。六个人有 MDM2 或 MDM4 的额外拷贝,10 个在称为 EGFR 的基因中具有与癌症相关的突变。该小组没有看到年龄与急性恶化疾病之间有任何相关性,但是他们确实注意到,其中 4 例具有额外的 MDM2 或 MDM4 基因的肿瘤和 EGFR 突变患者中的两个肿瘤生长得更快。

原始出处:

1. Heidi Ledford.Promising cancer drugs may speed tumours in some patients.NATURE. 2017 Mar 31.

2.Kato S, Goodman AM, Walavalkar V, et al. Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Mar 28.

3. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2016 Nov 8.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851403, encodeId=d6a418514034c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jan 01 08:45:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881841, encodeId=244a1881841f2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 10 02:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569976, encodeId=bb1d15699e60b, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Tue Apr 04 01:45:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184903, encodeId=60b518490392, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:50:34 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184820, encodeId=1fe71848207f, content=药物两面性!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Apr 03 09:49:11 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2018-01-01 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1851403, encodeId=d6a418514034c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jan 01 08:45:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881841, encodeId=244a1881841f2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 10 02:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569976, encodeId=bb1d15699e60b, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Tue Apr 04 01:45:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184903, encodeId=60b518490392, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:50:34 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184820, encodeId=1fe71848207f, content=药物两面性!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Apr 03 09:49:11 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2018-01-10 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1851403, encodeId=d6a418514034c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jan 01 08:45:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881841, encodeId=244a1881841f2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 10 02:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569976, encodeId=bb1d15699e60b, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Tue Apr 04 01:45:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184903, encodeId=60b518490392, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:50:34 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184820, encodeId=1fe71848207f, content=药物两面性!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Apr 03 09:49:11 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1851403, encodeId=d6a418514034c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jan 01 08:45:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881841, encodeId=244a1881841f2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 10 02:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569976, encodeId=bb1d15699e60b, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Tue Apr 04 01:45:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184903, encodeId=60b518490392, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:50:34 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184820, encodeId=1fe71848207f, content=药物两面性!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Apr 03 09:49:11 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 卡圣

    学习了,多谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1851403, encodeId=d6a418514034c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jan 01 08:45:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881841, encodeId=244a1881841f2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 10 02:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569976, encodeId=bb1d15699e60b, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Tue Apr 04 01:45:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184903, encodeId=60b518490392, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:50:34 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184820, encodeId=1fe71848207f, content=药物两面性!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Apr 03 09:49:11 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 lovetcm

    药物两面性!

    0

相关资讯

北京医院多科室联合完成罕见血管内肿瘤切除术

张女士今年52岁,患子宫肌瘤多年,虽然已到了绝经的年龄但仍有不规律的月经,且月经量很多。3个月前行腹盆CT检查时,医生发现张女士除了子宫肌瘤以外,右侧髂静脉还有占位,且一直延伸到下腔静脉,不除外子宫恶性肿瘤或下腔静脉血栓可能。张女士多方就医均被告知,手术风险很大,术中有大出血可能,且进一步的检查发现,肿物已经自下腔静脉长入了右心房,而且还有继续生长的趋势。张女士一家人多方打听找到了北京医院血管外科

肿瘤靶向用药有效率仅1.5%,未来肿瘤精准医疗发展有三大趋势

近两年来,精准医学治疗肿瘤疾病的理念逐渐被人们认同和理解,在全球各国的一致支持下,肿瘤精准医学正呈现蓬勃发展的繁荣景象。然而肿瘤疾病具有复杂多变和治疗困难等特点,想真正实现精准治疗的美好愿景并不容易。在近日的“医疗大数据应用与实践研讨会”上,志诺维思基因科技有限公司CEO兼首席科学家凌少平,就对肿瘤精准医学中的基因组大数据分析与应用的相关内容作了演讲报告。凌少平直言,靶向测序指导下的有效治疗患

Am J Resp Crit Care:巨噬细胞弹性蛋白酶诱导TRAIL介导的肿瘤细胞死亡

由此可见,MMP12的CTD启动的TRAIL介导肿瘤细胞死亡是通过其保守的SR20多肽。

美国发布NGS肿瘤panel验证指南

美国分子病理学学会(AMP)和美国病理学会(CAP)近日公布了基于二代测序的肿瘤panels验证指南,以提高实验室测序结果的质量,为患者提供更好的临床医疗服务。具体指南发表于《The Journal of Molecular Diagnostics》杂志上,包括了靶向测序方法和数据分析的概述、新检测方法的注意事项以及试验验证和质量控制指标的实施建议。 指南制定组主席,芝加哥Ann and Rob

清华大学张明徽:将NKT治疗肿瘤技术带到临床

清华大学医学中心细胞治疗研究所所长张明徽的NKT免疫细胞对于肿瘤的突破性治疗技术,在社会上引起强烈反响。迄今为止,已有近百位肝癌、肺癌、胃癌、前纵隔肉瘤等患者接受这一治疗技术,多位患者生存期超过四年。

J Mol Diagn:美国发布NGS肿瘤panel验证指南

美国分子病理学学会(AMP)和美国病理学会(CAP)近日公布了基于二代测序的肿瘤panels验证指南,以提高实验室测序结果的质量,为患者提供更好的临床医疗服务。具体指南发表于《The Journal of Molecular Diagnostics》杂志上,包括了靶向测序方法和数据分析的概述、新检测方法的注意事项以及试验验证和质量控制指标的实施建议。

Baidu
map
Baidu
map
Baidu
map